(Q43563141)

24 November 2017

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases (English)

1 reference

24 November 2017

1 reference

1 reference

3

1 reference

24 November 2017

Berenson JR

1

1 reference

24 November 2017

Rosen LS

2

1 reference

24 November 2017

Porter L

4

1 reference

24 November 2017

Coleman RE

5

1 reference

24 November 2017

Morley W

6

1 reference

24 November 2017

Dreicer R

7

1 reference

24 November 2017

Kuross SA

8

1 reference

24 November 2017

Lipton A

9

1 reference

24 November 2017

Seaman JJ

10

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

24 November 2017

1 reference

24 November 2017

91

1 reference

24 November 2017

1191-1200

1 reference

24 November 2017

7

1 reference

Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study

24 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

High dose pamidronate: clinical and biochemical effects in metastatic bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

21 January 2018

Ibandronate in oncology

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010401%2991%3A7%3C1191%3A%3AAID-CNCR1119%3E3.0.CO%3B2-0

10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference